Ionis Pharmaceuticals (IONS) guided to north of $5 billion in peak sales for its current programs on Tuesday. Early Wednesday, Ionis stock was approaching a six-year high after snagging a price-target hike.The guidance includes roughly$2 billion from drugs in development with partners and $3 billion from unpartnered programs, Needham analyst Joseph Stringer said in a report.The lion's share of the unpartnered revenue guidance falls on the success of a drug called olezarsen in lowering high triglycerides an ...